AI Article Synopsis
Article Abstract
Alzheimer's disease (AD) is the most widespread neurodegenerative disorder. Recently, it was found that mucus extract from has beneficial effects on memory and cognitive processes in a rat scopolamine model of AD. The present study elucidated the mechanisms of action of standardized mucus snail extract (SE) enriched with a fraction above 20 kDa on Alzheimer-type dementia in rats. Using proteomic analysis on two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) on rat cortex extracts, we compared protein expression in both groups: the first group was treated intraperitoneally with scopolamine (Sco, 2 mg/kg, 11 days) and the second (Sco + SE) group was treated intraperitoneally with Sco (Sco, 2 mg/kg) and protected by SE (0.5 mL/100 g bw) applied daily orally for 11 days. Brain cortex was separated and the expressions of various proteins related to memory and cognitive functions were identified. We found that the expression of Ubiquitin carboxyl-terminal hydrolase isozyme L1, Calbindin, Vacuolar ATP synthase catalytic subunit A, Tropomyosin beta chain, 14-3-3 zeta/delta, Kinesin-1 heavy chain, and Stathmin-4 significantly differs in SE-protected rats as compared to dement animals treated only by Sco, and these brain proteins might be potential therapeutic targets for Alzheimer's-type dementia treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11596839 | PMC |
| http://dx.doi.org/10.3390/molecules29225375 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug-Induced Cognitive Impairment.
Drug Saf
December 2024
Division of Neurology, Department of Clinical Sciences Lund, Lund University, Box 117, 22100, Lund, Sweden.
Drug-induced cognitive impairment (DICI) is a well-established, yet under-recognised, complication of many types of pharmacological treatment. While there is a large body of scientific literature on DICI, most papers are about drug-induced dementia in the elderly and one specific drug class. However, DICI also comprises subclinical symptoms, domain-specific forms of cognitive impairment as well as mild cognitive impairment (MCI), and delirium.
View Article and Find Full Text PDFGut-brain axis and neuroplasticity in health and disease: a systematic review.
Radiol Med
December 2024
Medical Physics Department, Bambino Gesù Children's Hospital, 00165, Rome, Italy.
The gut microbiota emerged as a potential modulator of brain connectivity in health and disease. This systematic review details current evidence on the gut-brain axis and its influence on brain connectivity. The initial set of studies included 532 papers, updated to January 2024.
View Article and Find Full Text PDFCovert Critical Illness Encephalopathy: Impairments That Escape Detection by Guideline Recommended, Protocolized Assessments.
Crit Care Med
December 2024
Department of Neurology, Northwestern University, Chicago, IL.
Objectives: To determine whether cognitive impairments of important severity escape detection by guideline-recommended delirium and encephalopathy screening instruments in critically ill patients.
Design: Cross-sectional study with random patient sampling.
Setting: ICUs of a large referral hospital with protocols implementing the Society of Critical Care Medicine's ICU Liberation Bundle.
Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab.
NEJM Evid
January 2025
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston.
Background: Concerns persist regarding the cognitive safety of achieving very low levels of low-density lipoprotein (LDL) cholesterol. Although short-term studies are reassuring, the long-term cognitive effects of sustained exposure to very low LDL cholesterol levels through combined proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibition and statin therapy remain unknown.
Methods: This prospective study enrolled a subset of adults with atherosclerotic cardiovascular disease who had completed a neurocognitive substudy (EBBINGHAUS) of a placebo-controlled randomized trial of evolocumab (FOURIER) and were eligible for a long-term open-label extension.
Acceptability, Feasibility, and Effectiveness of Concurrent High-Definition Transcranial Direct Current Stimulation and Cue Exposure in Cannabis Use Disorder: A Pilot Double-Blind Randomized Controlled Trial.
J ECT
December 2024
From the Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Objectives: We studied the acceptability, feasibility, tolerability, and preliminary effectiveness of combined cue exposure and anodal high-definition transcranial direct current stimulation (HD-tDCS) on the right dorsolateral prefrontal cortex (DLPFC) on cannabis craving in cannabis use disorder (CUD).
Methods: We randomly assigned 48 participants equally in 4 groups: A, tDCS and cannabis cue exposure; B, tDCS and neutral image; C, sham tDCS and cue exposure; and D, sham tDCS and neutral image. The images were validated by Delphi consensus.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!